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The immune system, and in particular, cytotoxic CD8+ T cells (CTLs), plays a vital part
in the prevention and elimination of tumors. In many patients, however, CTL-mediated
tumor killing ultimately fails in the clearance of cancer cells resulting in disease
progression, in large part due to the progression of effector CTL into exhausted CTL.
While there have been major breakthroughs in the development of CTL-mediated
“reinvigoration”-driven immunotherapies such as checkpoint blockade therapy, there
remains a need to better understand the drivers behind the development of T cell
exhaustion. Our study highlights the unique differences in T cell exhaustion development
in tumor-specific CTL which arises over time in a mouse model of mesothelioma.
Importantly, we also show that peripheral tumor-specific T cells have a unique expression
profile compared to exhausted tumor-infiltrating CTL at a late-stage of tumor progression
in mice. Together, these data suggest that greater emphasis should be placed on
understanding contributions of individual microenvironments in the development of
T cell exhaustion.
Keywords: cancer, CD8+ T cells, T cell exhaustion, tumors, peripheral lymphoid organs
INTRODUCTION
With more than 1.5 million new cancer diagnoses annually in the US alone and increased numbers
worldwide, cancer remains a major public health concern with high incidences of morbidity and
mortality. The immune system plays a vital part in preventing and eliminating tumor cells. In
particular, cytotoxic CD8+ T cells (CTL) are well-recognized for their role in surveillance and
killing of tumor cells. In many patients, however, CTL-mediated tumor killing ultimately fails
in the clearance of cancer cells resulting in disease progression. During chronic viral infection,
such as human immunodeficiency virus (HIV) infection or hepatitis C virus (HCV) infection in
humans or some strains of lymphocytic choriomeningitis virus (LCMV) in mice, virus-specific
CTL develop an “exhausted” phenotype. CTL exhaustion is a cell-intrinsic alteration resulting in
decreased functionality and effector capabilities as well as depressed proliferative capacity and
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increased apoptosis of the cell. This exhaustion has been shown
to be induced by chronic antigen stimulation and is primarily
mediated by T cell receptor (TCR) stimulation (1, 2). A hallmark
of CTL exhaustion is the progressive up-regulation of a selection
of surface markers and receptors known collectively as inhibitory
receptors (such as CTLA-4, PD-1, Lag3, 2B4, and CD160) (3).
Simultaneously, CTL begin to lose effector functions including
the ability to proliferate (and to produce IL-2), cytotoxic capacity,
and the production of the pro-inflammatory cytokines IFNγ,
and TNFα (3). Ultimately, the exhausted cell becomes pro-
apoptotic and is prone to activation-induced cell death upon TCR
engagement or Fas-mediated apoptosis (4, 5).
Earlier studies have demonstrated that, similar to chronic
infection, tumor-specific CTL are functionally exhausted and
can be re-invigorated by immune checkpoint blockade. Recently,
the inhibitory effects of CTLA-4 and PD-1 have become major
targets in cancer immunotherapies with the development of
checkpoint blockade therapeutics such as anti-CTLA-4 and
anti-PD-1 antibodies (6–9). These blocking antibodies prevent
signaling through the inhibitory receptors, thus enhancing T
cell function in vivo (10). The combined use of anti-CTLA-
4 and anti-PD-1 blockade in patients with melanoma cancer
has now become a first-line treatment after clinical trials. This
therapy has demonstrated the potential efficacy and remarkable
reduction of tumor burden in some late-stage melanoma patients
(11). Indeed, the major finding that targeting the CTLA-
4 pathway via antibody blockade can enhance anti-tumor
responses was first demonstrated in a preclinical mouse model
(12), highlighting the relevance and usefulness of murine cancer
model systems.
Despite these major advances and breakthroughs however,
there remains a great need to better understand the mechanisms
by which the immune system and CTL fail in the context
of solid tumors (13), as not all patients respond to the
current antibody blockade therapies (6, 9, 11). We therefore
sought to characterize the development of T cell exhaustion
in a murine mesothelioma model expressing ovalbumin,
AE17sOVA, which exhibits histological and morphological
similarities to human mesothelioma tumors (14, 15). In this
model, we observed that naïve OT-I CD8+ T cells, transgenic
CD8+ T cells that recognize the SIINFEKL peptide from
OVA, adoptively transferred concurrently with tumor cells
differentiate into effector CTL by day 15 and developed
characteristics of T cell exhaustion by the late end-point day
22. We also observed that the level of exhaustion was site-
specific, exhibiting a gradient of T cell exhaustion which was
highest in intra-tumor tumor-specific CTL and progressively
decreased in the draining lymph node and further declined
in splenic tumor-specific CTL. Taken together, these findings
demonstrate that spatial and temporal determinants impact
the degree of exhaustion in tumor-specific CTL in the
AE17sOVA mesothelioma mouse model. Understanding such
determinants in mesothelioma may instruct the timing of
checkpoint inhibition and optimal location from which neo-
antigen-specific CTL are derived for adoptive transfer therapies.
Such optimization may lead to an improvement in the efficacy
of immunotherapies.
MATERIALS AND METHODS
Animals and Infections
For influenza virus infections and AE17sOVA tumor
experiments: C57BL/6 Tg(TcraTcrb)1100Mjb/J (OT-I) were
backcrossed with B6.SJL-Ptprca Pepcb/BoyJ (CD45.1+) mice
(both from the Jackson Laboratory) to generate OT-I CD45.1+
mice on the C57BL/6J background. C57BL/6J mice were kept
under SPF conditions at Erasmus University Medical Center
or at Sanford Burnham Prebys Medical Discovery Institute (an
AAALAC certified animal facility). This study was carried out
in accordance with the recommendations of the Instantie voor
Dierenwelzijn (IvD) (protocols were approved by the IvD), and in
accordance with the recommendations of the Sanford Burnham
Prebys Medical Discovery Institute Institutional Animal Care
and Use Committee (IACUC) (protocol number 18-067).
For influenza virus infections: 8–10 week-old female mice
received an intravenous injection of 1 × 104 OT-I CD45.1+
CD8+ T cells from an uninfected OT-I female mouse of 8–
10 weeks of age; 3 h later, mice were anesthetized with 2.5%
isoflurane gas and were infected intranasally with influenza virus
strain A/WSN/33 expressing OVA(257−264)(WSN-OVA(I); a gift
from D. Topham, University of Rochester Medical Center).
For tumor injections: 8–10 week-old female mice received
an intravenous injection of 1 x 104 OT-I CD45.1+ CD8+ T
cells from an uninfected OT-I female mouse 8–10 weeks of age;
3 h later, mice were anesthetized with 2.5% isoflurane gas. The
hind flank was shaved, then 5 × 105 AE17sOVA cells, an OVA-
expressing murine mesothelioma cell line derived from C57BL/6
mice (14), were injected subcutaneously in 100 µL total volume
of sterile 0.9% normal saline.
Cell Culture
AE17 and AE17sOVA cells were maintained in RPMI
1640 supplemented with 10% FBS, 100 units/mL
Penicillin/Streptomycin (ThermoFisher, Waltham, MA), 2mM
L-glutamine (ThermoFisher), 0.05mM 2-mercaptoethanol
(ThermoFisher), and were cultured at 37◦C in 5% CO2;
AE17sOVA media was additionally supplemented with 400 µg/L
G418 (ThermoFisher). For all experiments, cells were passaged
in vitro three times prior to injection into mice. AE17sOVA cells
were confirmed to be mycoplasma free and re-checked every 6
months. OVA expression of AE17sOVA cells and OT-I responses
were confirmed by the activation of naïve OT-I cells in in vitro
cultures compared to non-OVA expressing AE17 control cells.
Flow Cytometry
Single-cell suspensions were generated from spleens and lymph
nodes by mechanical disruption and passed through a 40µM
cell strainer (Falcon, San Jose, CA). Lungs and tumors were
digested by chopping tissues into 1 mm3 sections and incubating
sections in tissue-culture treated petri dishes for 2 h in RPMI
1640 containing 3mg/mLCollagenase A and 0.75mg/mLDNAse
I (both from Worthington Biochemical, Lakewood, NJ). Cells
were stained as previously described (16). Briefly, in all stains,
cells were pre-treated with anti-CD16/32 (Fc Block; 2.4 G2;
BioLegend, San Diego, CA) for 15min before continuing with
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surface staining. For surface stains, cells were stained for 20min
on ice. Cells were stained with the following fluorochrome
conjugated monoclonal antibodies: CD8a (clone 53–6.7), CD45.1
(clone A20), CD45.2 (clone 104), Thy1.1/CD90.1 (clone HIS51)
(all from eBioscience/ThermoFisher, San Diego, CA), CD25
(clone PC61), CD69 (clone H1.2F3), CD44 (clone 1M7), CD62L
(clone MEL-14) (all from BD Bioscience, San Jose, CA), KLRG1
(clone 2F1/KLRG1), IL-7R/CD127 (clone A7R34), PD-1 (clone
29F-IAI2) (all from BioLegend, San Diego, CA). Cells were
also stained with Cy5.5-labeled Annexin V (BD Biosciences)
and APC labeled-tetramers of H-2b major histocompatibility
complex class I loaded with OVA(257−264) (prepared in the lab)
(17) (e.g., SIINFEKL). After staining, cells were washed 2 times
with HBSS containing 3% FBS and 0.02% sodium azide and
fixed with 1% formaldehyde. For Annexin V staining, all buffers
contained 2.5mM CaCl2. For staining of intracellular cytokines,
cells were stimulated with SIINFEKL peptide (Anaspec, Fremont,
CA) for 6 h at 37◦C, 5% CO2 in the presence of GolgiPlug
(BD Biosciences) and a fluorochrome-conjugated monoclonal
antibody against CD107a (clone ID4B) or isotype control. Cells
were surface stained as above including additional CD107a
antibody (clone ID4B) or the appropriate isotype control (both
Biolegend), then fixed overnight at 4◦C with IC Fixation Buffer,
washed using Perm/Wash buffer (eBioscience) and stained
for intracellular cytokines for 45min at 4◦C. Fluorochrome
conjugated anti-IFNγ monoclonal antibody (clone XMG1.2),
anti-TNFα monoclonal antibody (clone MP6-XT22) or the
appropriate isotype controls (all from eBioscience) were used
for intracellular stains. After staining, cells were washed twice
with Perm/Wash buffer (eBioscience) and fixed with 1%
formaldehyde. For staining of transcription factors, cells were
surface stained as above then fixed for 1 h at 4◦C with FoxP3
Fixation Buffer, washed using Perm/Wash buffer (eBioscience)
and stained for transcription factors for 1 h at 4◦C. The following
antibodies were used in combination with intracellular flow
cytometry: anti-T-bet antibody (clone 4B10, BioLegend), anti-
Eomes antibody (clone DAN11MAG, eBioscience), anti-Ki67
antibody (clone 16A8, BioLegend), or the appropriate isotype
controls. After staining, cells were washed twice with Perm/Wash
buffer (eBioscience) and fixed with 1% formaldehyde. All samples
were collected with an LSR-Fortessa (BD Biosciences) and
analyzed with FlowJo v10 software (Treestar, Ashland, OR). For
some figures, the program SPICE (Simplified Presentation of
Incredibly Complex Evaluations) (18) was used to generate bar
graphs and pie graphs. In brief, Boolean gating was performed
on donor OT-I CD8+ T cells for the indicated populations using
FlowJo v10 (BD Biosciences). The data were then imported into
SPICE to generate the figures shown here.
tSNE Analysis
In brief, the Unbiased hierarchal t-Distributed Stochastic
Neighbor Embedding (tSNE) analysis was performed using the
tSNE FlowJo v10 plugin on a single pooled sample of donor
cells reflective of an equal number of cells from each mouse
and each tissue (tumor, spleen, tumor draining lymph node).
The following parameters were assessed: PD-1, 2B4, CD69, T-bet,
and Eomes. In detail, on a per experiment basis, CD8+CD45.1+
donor OT-I cells were concatenated within each tissue, using
compensated parameters. Concatenated files from like tissues of
individual mice were further concatenated using compensated
parameters to form three total samples: one each of spleen, tumor
draining lymph node (DLN), and tumor. Each file was down-
sampled to 1,220 total events reflective of the greater population.
The three down-sampled populations were concatenated into
one file, then tSNE was run for 1,000 iterations with the following
selected parameters: PD-1, 2B4, CD69, T-bet, and Eomes.
Statistics
For flow cytometry, the normality of the population distribution
was assessed using the Shapiro-Wilk normality test by GraphPad
Prism 8. Significant differences between normally distributed
populations were assessed using a two-tailed, unpaired t-test;
significant differences between non-normally distributed
populations were assessed using a two-tailed Mann Whitney
exact test. The tests performed are denoted in each figure legend
and subsequent p-values are annotated in the associated figure.
RESULTS
OVA-Specific CTL Become Progressively
Exhausted in the AE17sOVA Mesothelioma
Tumor Model and Lose Proliferative
Capacity
The AE17 mesothelioma cell line was generated by the injection
of asbestos fibers intraperitoneally into C57BL/6 mice. To
generate the AE17sOVA tumor cell line, AE17 tumor cells
were transfected with full-length secretory ovalbumin (OVA)
(14, 15). AE17sOVA cells can generate in vivo OVA-specific T
cell responses (14) and this model is therefore suitable for in
vivo tracking of both endogenous and adoptively-transferred
antigen-specific CD8+ T cells. We found that subcutaneous
injection of 5 × 105 AE17sOVA into the hind-flank of adult
female wild-type mice that had received an injection of 1 ×
104 OT-I CD8+ T cells 3 h prior resulted in the reproducible
growth of vascularized tumors (Figure 1A). This growth curve
allowed us to identify two time points of interest: day 15, a
time point characteristic of slow but steady tumor growth; and
day 22, when tumor growth had increased. At day 15 and
day 22 post-injection of both tumor cells and OT-I T cells,
the tumors, spleen, and draining and non-draining inguinal
lymph nodes (DLN and NDLN, respectively) were collected
and analyzed by flow cytometry. The adoptive transfer of 1 ×
104 naïve OT-I CD45.1+ CD8+ T cells followed by hind-flank
injection of 5 × 105 AE17sOVA tumor cells into recipient mice
resulted in a robust intratumoral donor cell response. Donor
cells were identified by the congenic marker CD45.1 and an
appreciable endogenous CD8+ T cell response was detected by
tetramer staining of CD45.1− (host) OVA(257−264)-specific CTL
(Figure 1B). We additionally observed the recruitment of tumor-
specific donor OT-I cells into the inguinal DLN (tumor-bearing
side) and NDLN (non-tumor-bearing side) and spleens of mice
(Figures 1C,D). We next sought to evaluate if the intratumoral
antigen-specific CTLwere exhausted, and how early an exhausted
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FIGURE 1 | Recruitment and expansion of donor OT-I CD8+ T cells to the tumor site and peripheral lymphoid organs upon injection of AE17sOVA
mesothelioma tumor cells. Adult (8–10 weeks) female C57BL/6 mice received an intravenous injection of 1× 104 naïve OT-I CD45.1+ CD8+ T cells followed 3 h later by a
(Continued)
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FIGURE 1 | subcutaneous injection of 5 × 105 AE17sOVA murine mesothelioma tumor cells in the hind flank. (A) Solid, measurable AE17sOVA tumors developed
over time, reaching an average of 100 mm3 in size at approximately 10 days post-injection. Tumor size was recorded every other day, and tumors, inguinal draining
(DLN) and non-draining (NDLN), and spleens were collected at the indicated time points. Data is representative of >3 independent experiments, n = 8 mice with OT-I
and n = 7 mice without OT-I donor cells. (B) Representative FACS plots showing donor OT-I CD8+ T cells and endogenous tumor-specific CD8+ T cells within
AE17sOVA tumors of mice 15- and 22-days post-injection of tumor and the frequency of donor vs. endogenous OVA-specific CD8+ T cells as determined by staining
with MHC class I tetramer with SIINFEKL peptide. Dot plot/bar graph quantifying the individual and average mouse frequencies (C) and absolute numbers (D) and
overall average frequency of donor OT-I tumor-specific CD8+ T cells in the tumors, inguinal lymph nodes, and spleens. (E) Dot plot demonstrating the fold-expansion
of donor T cells within the tumors from the original 1 × 104 T cell infusion. (F) Dot plot/bar graph quantifying the individual mouse and overall average Ki67 expression
(MFI, median fluorescence intensity) in intratumoral OT-I CD8+ T cells at D22 relative to D15. For experiments B-F, data is representative of at least two experiments, n
= 4 (spleen, DLN, NDLN) at D15, n = 5 (tumor) at D15, n = 11–12 mice D22 AE17sOVA tumor injection. The frequencies and absolute cell counts of D15 samples
were normally distributed and D22 samples were not normally distributed. Two-tailed exact Mann Whitney tests were used to assess significance and significant data
(p < 0.05) is annotated within the individual graphs. The Shapiro-Wilk test determined that both D15 and D22 samples were normally distributed for Ki67 expression.
A two-tailed unpaired T-test was used to assess significance (p = 0.0001).
CTL phenotype was established within the AE17sOVA tumor
model. We observed a substantial expansion and recruitment of
donor OT-I T cells into the tumor at day 15 [5.0 × 106 ± 4.1
× 106]. However, this expansion did not persist after day 15 as
by day 22 donor OT-I cells decreased in frequency (87.97% of
total CD8+ T cells at day 15 vs. 11.72% of total CD8+ T cells at
day 22; p < 0.001) and subsequently the total number of donor
OT-I T cells compared to the earlier time point decreased also
(5.0 × 106 ± 4.1 × 106 on day 15 vs. 1.4 × 106 ± 1.1 × 106
on day 22) (Figure 1D). No significant changes in absolute OT-I
CTLs were observed in the spleens, DLN, or NDLN (Figure 1D).
Thus, donor OT-I cells within the tumor microenvironment
expanded by 100-fold during the first 15 days of slow tumor
growth but contracted during the subsequent exponential tumor
growth period (Figures 1A,E).
Loss of proliferative capacity is a hallmark of T cell exhaustion,
and we reasoned that this may explain the decreased numbers
of donor OT-I T cells in the tumors at day 22 post-injection of
tumor cells. We therefore assessed the level of Ki-67, a nuclear
protein expressed during all stages of the cell cycle (19), in the
donor OT-I CD8+ T cells as a marker of T cell proliferation.
The frequency of donor OT-I T cells expressing Ki-67 was
significantly less in day 22 intratumoral donor OT-I T cells
compared to day 15 donor T cells [96.26± 1.5 % day 15 vs. 48.44
± 20.29 % day 22; p < 0.001], indicating that fewer cells were
proliferating at the later time point (Figures 1E,F). Therefore,
the progressive decrease of donor OT-I cells in the tumors most
likely reflects the reduced ability of these donor cells to proliferate
within the tumor by day 22.
Progressive Exhaustion With Loss of
Polyfunctional Cytokine Producing
Capability in Donor OT-I Cells by Day 22
Post-tumor Injection
As an example of a highly efficient effector CTL response,
we chose to use anti-viral CTL during the primary response
to influenza virus for comparison with tumor-specific CTL.
Influenza-specific effector CTL are capable of clearing virally-
infected cells in vivo (20) and thus served as a basis for
comparison with the progressive functional exhaustion of anti-
tumor CTL. In both tumor and influenza virus models, we
utilized adoptive transfers of OT-I cells, thus circumventing
possible bias introduced by TCRs of varying affinities being
recruited in the respective responses. Effector CTL responding
to an acute viral infection such as influenza A virus will
upregulate activation markers and be recruited to the site
of viral infection such as the lungs. Similarly to influenza
virus-specific cells during acute infection, we found that
at day 15 tumor-specific (OVA(257−264) MHC-I Tetramer
+
OT-I) effector CTL that had migrated into the tumor site
displayed an activated phenotype including CD44 upregulation
and simultaneous downregulation of CD62L, IL-7R (CD127)
expression, and upregulation of CD69 (an early marker of T
cell activation) (Supplementary Figures 1A–E). In comparison,
tumor-specific CD8+ T cells in spleens, DLN and NDLN
largely maintained IL-7R expression despite CD44 upregulation,
and upregulation of CD69 was observed predominantly within
the DLN (Supplementary Figures 1F,G). We also observed
upregulation of KLRG1 by the OVA-specific CD8+ T cells in
all tissues tested, and to a greater degree than influenza-specific
donor OT-I CD8+ T cells (Supplementary Figures 1H,I).
We next evaluated the cytokine production of tumor-
specific CTL and in particular their polyfunctionality as loss
of such polyfunctionality is a hallmark of CTL exhaustion
(21). To assess polyfunctionality of tumor-specific CTL, tumor
cell suspensions were incubated with SIINFEKL peptide, the
cognate antigen recognized by OT-I CD8+ T cells (22) and
produced by the AE17sOVA tumor cell line (14), for 6 h
followed by intracellular staining for flow cytometry to assess the
production of the pro-inflammatory cytokines IFNγ and TNFα.
While intratumoral donor OT-I T cells 15 days post-injection
demonstrated the capacity to produce high levels of IFNγ either
alone (13.35 ± 6.43%) or in combination with TNFα (30.72
± 11.52%) (Figures 2A–C), the frequency of polyfunctional
cytokine producing intratumoral donor OT-I T cells 22 days
post-injection was significantly reduced (12.65 ± 10.96% day
22 vs. 30.72 ± 11.52% day 15; p = 0.0132) (Figures 2A–C).
When comparing the frequency of cytokine producing tumor
antigen-specific cells to day 10 OT-I from lungs of WSN-
OVA influenza virus infected mice, it was clear that while OT-
I from day 15 tumors and influenza virus primary response
retained the ability to produce cytokines and in particular co-
produce multiple cytokines, by day 22 the vast majority of OT-I
produced no cytokines and very few cells retained polyfunctional
capacity (Figures 2B,C). To ensure that the decreased cytokine
Frontiers in Immunology | www.frontiersin.org 5 January 2020 | Volume 10 | Article 3074
Hope et al. Microenvironment-Dependent CTL Exhaustion
FIGURE 2 | Progressive loss of cytokine production by intratumoral tumor-specific. Intratumoral donor OT-I CD8+ T cells were re-stimulated with SIINFEKL peptide
(10 uM) for 5 h in the presence of Brefeldin A, followed by intracellular cytokine staining to detect cytokine-producing donor (CD45.1+) OT-I CD8+ T cells. (A)
Representative FACS plots showing IFNγ and TNFα cytokine production by donor OT-I CD8+ T cells. (B) Bar graph comparing IFNγ and TNFα double positive (DP),
single positive (SP), or null producing donor OT-I CD8+ T cells at day 10 post-infection with WSN-OVA influenza (lungs) and days 15 and 22 post-injection of T
cells and tumors (tumors). (C) Pie charts comparing DP, SP, or null cytokine producing donor OT-I CD8+ T cells from the lungs at day 10 post-infection with WSN-OVA or
(Continued)
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FIGURE 2 | from the tumors at day 15 or day 22 post-injection of tumor cells. FACS analysis was performed using FlowJo v10, and data was imported into SPICE
6.0 for bar graph and pie chart figure production. For experiments (A–C), data is representative of at least two experiments, n = 4 at D10 WSN-OVA influenza virus
infection, n = 5 at D15, and n = 12 mice D22 AE17sOVA tumor injection; data is representative of one experiment, n = 3 at D15 WSN-OVA influenza virus infection.
All groups except D15 TNFα were normally distributed. When data was normal, a two-tailed unpaired T test was used to assess significance; when one sample set
was non-normally distributed, a two-tailed exact Mann Whitney test was used to assess significance. Significant data (p < 0.05) is annotated within the graph.
production was indeed reflective of functional exhaustion and
not a result of normal T cell kinetics or contraction, we similarly
evaluated the function of donor OT-I CD8+ T cells in the
lungs of WSN-OVA influenza virus infected mice 15 days post-
infection, during the contraction phase of the T cell response to
influenza virus infection (Supplementary Figures 2A–C). While
we did observe a decrease in frequency of IFNγ and TNFα co-
producing donor OT-I cells in the lungs at day 15 compared to
day 10 post-influenza virus infection, there was no significant
difference between cytokine production between OT-I from
day 15 post-influenza virus infection and day 15 AE17sOVA
tumors. Conversely, we observed significantly decreased (26.6
vs. 12.6%, p = 0.0007) co-production between OT-I from day
15 post-influenza virus infection and day 22 AE17sOVA tumors
(Figures 2B,C). Overall, OT-I cells at day 22 post-injection
displayed a more quiescent and less functional phenotype
compared to intratumoral OT-I cells from day 15 and this is
not simply due to changes occurring during the kinetics of an
antigen-specific CTL response.
Intratumoral Donor OT-I Cells Gradually
Acquire and Increase Co-expression of
Inhibitory Receptors
We subsequently evaluated the expression of inhibitory receptors
on intratumoral CTL as this is anothermajor feature of exhausted
CTL. We compared intra-tumor CTL from day 15 and day 22
tumors with effector CTL in lungs 10 days after WSN-OVA
influenza virus infection. In both model systems, as expected,
PD-1 is upregulated on responding T cells indicating its dual role
as both an activationmarker and inhibitory receptor (Figure 3A).
When comparing the frequency of inhibitory receptor (IR) co-
expression between day 10 lungs (influenza) and day 15 tumors
(AE17sOVA), we observed an increased frequency in donor
OT-I cells expressing 2 IR at day 10 influenza virus infection
(Figure 3B). Among intratumoral donor OT-I CD8+ T cells at
day 22 however, we observed a marked increase in the number
of IR co-expression compared to both day 10 influenza virus
infection and day 15 AE17sOVA tumors (Figures 3B,C). We also
evaluated IR expression on donor OT-I from the lungs of WSN-
OVA influenza virus mice at day 15 post-infection; strikingly,
we observed a significant increase in IR co-expression compared
to both day 10 influenza virus and both day 15 and day 22
tumors (Figures 3B,C, Supplementary Figure 2D). This may be
reflective of the donor cells entering the contraction phase of the
acute viral infection response and the persistence of antigen in
the lungs. This IR expression was not accompanied by functional
and proliferative defects and warrants further evaluation in the
future. In respect to the intratumoral donor OT-I cells in day 22
tumors, the increased co-expression of the inhibitory receptors
PD-1, LAG3, 2B4, and CD160 together with the significantly
reduced cytokine production indicates that these cells are more
phenotypically and functionally exhausted than their day 15
counterparts (Figures 3B,C).
The Degree of CTL Exhaustion
Development Is Influenced by the Physical
Location of CTL
It is well-established that the tumor microenvironment is
highly immunosuppressive and modulated by the tumor cells
themselves as well as the recruitment of immunosuppressive
CD4+CD25+FoxP3+ regulatory T cells (Tregs), CD11b
+Gr-1+
myeloid-derived suppressor cells (MDSC), and M2-polarized
macrophages (23–25). It has also been demonstrated in patients
that tumor draining lymph nodes exert immunosuppressive
capacity (26) despite also serving as a site for peripheral tumor-
specific T cell activation and immune-surveillance (27). To
evaluate how different microenvironments and spatial locations
could influence the CTL profile, we performed an unbiased
hierarchal clustering analysis using the T-distributed Stochastic
Neighbor Embedding (t-SNE) machine learning algorithm in
FlowJo v10. For this analysis, we compared donor OT-I T cells
from the spleens, tumor-draining inguinal lymph nodes, and
tumors in mice 22 days post-tumor injection. Individual samples
were concatenated, downsampled to equal numbers between
tissues, and concatenated again before running tSNE on the
expression of the activation and inhibitory receptor markers
PD-1, 2B4, CD69, and the transcription factors T-bet (Tbx21,
a T-box transcription factor) and Eomes (Eomesodermin). The
resultant contour tSNE plot (Figure 4A, left) depicts the relative
similarities and differences between individual cells from all
samples in an unbiasedmanner. tSNE analysis showed that donor
OT-I T cells clustered uniquely with donor OT-I cells isolated
from their same tissue of origin (Figure 4A, right). Interestingly,
donor OT-I cells from the tumor-draining inguinal lymph nodes
displayed an intermediary phenotype between donor cells from
the spleen and tumor (Figure 4B). Overlaying PD-1, 2B4, and
the transcription factor T-bet expression levels onto the tSNE
plots showed expression of PD-1 and 2B4 primarily in the tumor
clusters, while T-bet expression was predominately in splenic
clusters (Figure 4C). One major difference between the splenic
and tumor cells was the percentage of donor cells expressing
Ki67. While donor cells within spleens were largely Ki67+ (78.58
± 5.47%), only 48.44± 20.29% of donor cells in tumors expressed
Ki67 (p < 0.001) (Figures 4D,E). This is in contrast to the
maintained Ki-67 expression frequency of day 15 donor OT-I
cells fromWSN-OVA influenza virus in both the lung and spleen
(Supplementary Figures 2D,F). Notably, we confirmed that T-
bet expression was markedly different in donor OT-I T cells
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FIGURE 3 | Intratumoral tumor-specific T cells show upregulated inhibitory receptor co-expression at day 22, but not day 15 post-injection. Activation
marker/inhibitory receptor (PD-1, Lag3, 2B4, CD160 for influenza D10, tumor D15 and D22; PD-1, Lag3, and TIM-3 for influenza D15) expression was assessed by
ex vivo flow cytometry analysis of donor OT-I CD8+ T cells from the lungs (WSN-OVA influenza) or tumors at the indicated time points. (A) Representative FACS plots
showing single or co-expression of PD-1 and 2B4 on donor and endogenous tumor-specific CD8+ T cells from day 15 or day 22 AE17sOVA tumor-bearing mice. (B)
Bar graph comparing the frequency of donor OT-I CD8+ T cells expression of 0, 1, 2, 3, or 4 activation markers/inhibitory receptors (PD-1, Lag3, 2B4, CD160) as
determined by Boolean gating. (C) Pie charts comparing the overall frequency of inhibitory receptor expression on OT-I CD8+ T cells from the lungs at
day 10 post-infection withWSN-OVA or from the tumors at day 15 and day 22 post-injection of tumor cells. FACS analysis was performed using FlowJo v10, and data was
(Continued)
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FIGURE 3 | imported into SPICE 6.0 for bar graph and pie chart figure production. For experiments (A–C), data is representative of at least two experiments, n = 4 at
D10 WSN-OVA influenza virus infection, n = 5 at D15 and n = 12 mice D22 AE17sOVA tumor injection; data is representative of one experiment, n = 3 at D15
WSN-OVA influenza virus infection. For influenza groups at D10, groups 0, 1, and 2 were normally distributed. For influenza groups at D15, all groups were normally
distributed. For AE17sOVA groups at D15, groups 0, 1, 2, and 4 were normally distributed. For AE17sOVA groups at D22, groups 0, 1, and 2 were normally
distributed. All others were non-normally distributed. When data was normal, a two-tailed unpaired T-test was used to assess significance; when one sample set was
non-normally distributed, a two-tailed exact Mann Whitney test was used to assess significance. *p < 0.05; **p < 0.005; ***p = 0.0001; ****p < 0.0001.
in a tissue-dependent manner (Figures 4F,G). T-bet expression
has been associated with effector and effector memory CD8+
T cells (28, 29); however, during chronic antigenic stimulation,
continued TCR stimulation can result in the loss of T-bet
expression in CD8+ T cells accompanied by CTL exhaustion
(30, 31). Further confirming that this loss of T-bet expression is
not simply a result of the kinetics of the CD8+ T cell response,
we found that influenza virus specific donor OT-I CD8+ T cells
in the lungs at day 15 post-infection maintained higher levels
of T-bet expression compared to donor OT-I cells within the
spleens of the samemice (Supplementary Figures 2G,H). Others
have described that decreased T-bet and increased expression of
another transcription factor, Eomesodermin (Eomes), in T cells
is associated with T cell exhaustion, particularly in HIV-specific
CD8+ T cells (32). We only observed a noticeable shift in T-bet
between the day 15 and day 22 intratumoral antigen-specific OT-
I T cells, and did not observe upregulation of Eomes in day 22
donor OT-I cells within the tumors compared to the spleen and
DLN (Figure 4I).
We additionally compared cytokine production by donor OT-
I cells in the spleens to their matched tumors at day 22. Unlike
intratumoral donor OT-I CD8+ T cells, splenic-derived OT-I
CD8+ T cells maintained cytokine production (51.18 ± 15.38%
cytokine producing donors in spleens vs. 26.54 ± 14.38 cytokine
producing donor cells in tumors) at day 22 post-tumor injection;
and significantly more polyfunctional donor cells were also found
in spleens (21.64 ± 9.149% vs. 12.96 ± 10.38%, p = 0.043)
(Figure 4H). This is contrary to our findings in day 15 post-
influenza virus infection in which the frequency of IFNγ and
TNFα co-producing donor OT-I cells was unchanged between
the lung and spleen (Supplementary Figure 2B).
The above data taken together, demonstrate a clustering
of anti-tumor CTL phenotypes depending on location and a
decreasing gradient of anti-tumor CTL exhaustion from the
tumor to the draining lymph nodes to the spleen.
DISCUSSION
Understanding mechanisms driving T cell exhaustion is central
to the development and novel application of immunotherapies
to different types of cancer. Upon TCR activation, PD-
1 is upregulated on effector T cells in response to most
stimuli, including in response to acute viral infection such
as influenza virus (33). However, continuous TCR stimulation
drives maintained and increased expression of PD-1 as well as
the co-expression of additional inhibitory receptors, thereafter,
serving as a marker of T cell exhaustion. The general mechanisms
of PD-1-mediated inhibition of effector T cell responses have
been previously described (34), and it is important to note that
PD-1, although well-studied, is not the only intrinsic mechanism
involved in the development of T cell exhaustion. It is clear
that intrinsic molecular pathways including signaling initiated
by ligation of other surface molecules such as CD160, TIM-3,
and CTLA-4 promote T cell inhibition and play a central role
in T cell exhaustion (35–37). Further, the success of antibody-
mediated blockade of inhibitory receptors to limit further
exhaustion and restore T cell function underscores the need to
identify additional targetable mediators and pathways of T cell
exhaustion, particularly in the context of cancer (38, 39).
Exhaustion in CD8+ T cells can be described as a multi-
factorial phenotype based on a combination of surface marker
expression (e.g., co-expression of inhibitory receptors),
decreased functionality (e.g., decreased pro-inflammatory
cytokine production, decreased cytotoxic capability), and
decreased proliferative capacity. Together, this results in a CTL
population that is incapable of clearing a chronic infection
or tumor. Our study clearly demonstrates that the level of
exhaustion in CTL is either influenced or determined by the
distinct microenvironment where the T cells are isolated.
In our studies involving AE17sOVA, we observed that both
adoptively transferred OT-I cells and endogenous OVA-specific
CTL (data not shown) were characteristically more exhausted
when analyzed ex vivo from tumors vs. DLNs where an
intermediate T cell exhaustion phenotype was observed, and
spleens where effector cells did not manifest an exhausted
phenotype, as expected. Taken together, the increased inhibitory
receptor expression, decreased cytokine production, decreased
proliferative capacity, and decreased T-bet expression observed
in day 22 post-tumor donor OT-I T cells indicate that tumor-
specific T cells in the AE17sOVA mesothelioma tumor model
develop characteristic T cell exhaustion. The development
of this exhausted T cell (TEX) phenotype in the donor OT-I
T cells is likely a result of sustained exposure to the tumor
microenvironment and prolonged antigen exposure. This is
exemplified by the fact that intratumoral donor OT-I T cells
assessed at the earlier day 15 timepoint more closely resembled
effector influenza-specific donor OT-I T cells from the lungs of
mice during the peak of the CTL response to acute influenza
virus infection. Our characterization demonstrates that the
AE17sOVA mesothelioma tumor model is therefore a suitable
model for evaluating the kinetics of T cell exhaustion in the
context of cancer, with day 15 intratumoral donor OT-I T cells
being “pre-exhausted,” while donor OT-I T cells on day 22
reflect an “exhausted” phenotype for CTL analysis. Our data
also suggests that the development of CTL exhaustion in the
AE17sOVA murine mesothelioma tumor model has both spatial
and temporal requirements. Whereas intratumoral donor OT-I
T cells at day 15 post-injection have a phenotype that more
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FIGURE 4 | The tissue microenvironment influences the development of exhaustion in CTL. tSNE analysis of donor OT-I CD8+ T cells from tumors, tumor DLN,
and spleens at day 22 post-injection was performed based on PD-1, 2B4, CD160, T-bet, and Eomes expression using FlowJo v10. (A)Contour tSNE FACS plot showing
(Continued)
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FIGURE 4 | the relatedness of each representative donor cell from the tumors, tumor DLN, and spleens (left) and overlaid with the cells from each tissue of origin
(tumor = red, tumor DLN = orange, spleen = blue) (right). (B) Overlays of cells from the individual tissues of origin on the overall (gray) contour tSNE FACS plot.
(C) Median fluorescent intensity gene expression overlays of PD-1, 2B4, and T-bet expression in individual cells. (D) Representative FACS plots showing Ki67
expression in CD45.1+ donor OT-I CD8+ T cells compared to all CD8+ T cells in the spleen (left) and tumor (right) at day 22 post-injection. (E) Dot plot/bar graph
showing the individual and average frequency of Ki67+ donor OT-I CD8+ T cells in the respective tissues. (F) Representative FACS plot showing T-bet expression in
donor OT-I cells in the tumor and spleen at day 22 post-injection. (G) Relative T-bet expression in donor OT-I cells in the tumor, spleen, and DLN at day 22
post-injection. (H) Dot plot/bar graph comparing the frequency of cytokine-producing donor OT-I T cells from the spleens and tumors of mice at day 22 post-injection.
Connecting lines pair matched samples from the same recipient host mouse. (I) Representative FACS plots showing T-bet and Eomes expression in CD45.1+ donor
OT-I CD8+ T cells in the respective tissues at day 22 post-injection of AE17sOVA tumor cells. For experiments A-H, data is representative of at least two experiments,
n = 11–12 mice. All groups were normally distributed except the D22 tumor TNFα SP group. When data was normal, a two-tailed unpaired T test was used to assess
significance; when one sample set was non-normally distributed, a two-tailed exact Mann Whitney test was used to assess significance. Significant data (p < 0.05) is
annotated within the graph.
closely resembles effector CTL during acute viral infection, day
22 tumor-derived donor OT-I T cells have highly upregulated
inhibitory receptor expression, decreased proliferative capacity
and cytokine production, and have downregulated T-bet
expression levels. By comparison, tumor-specific donor CD8+ T
cells in the periphery at day 22 demonstrate a gradient of T cell
exhaustion based on their physical location. Those T cells within
the tumor have the highest measurable level of T cell exhaustion,
while T cells within tumor DLN are more exhausted than splenic
T cells but less so than intratumoral T cells. In conclusion, these
data support the use of the AE17sOVA mesothelioma tumor
model as a means of evaluating the effectiveness and timing
of anti-tumor therapeutic interventions and enhancing our
understanding of the basic requirements for the development of
T cell exhaustion in cancer.
The differing levels of CTL exhaustion could be a result of
the cellular composition of individual microenvironments, as
it is already well-established that the tumor microenvironment
can be highly immunosuppressive. Tumor sites are heavily
infiltrated by immunosuppressive MDSC, Tregs, and M2-
polarized anti-inflammatory macrophages [see (40)]. Murine
mesothelioma induces locally-proliferating IL-10+TNF-
αCD206−CX3CR1+ M3 macrophages that can be selectively
depleted by chemotherapy or immunotherapy (40). In addition
to creating an anti-inflammatory environment, these cells also
produce factors that can directly promote tumor growth and
vascularization such as matrix metallopeptidase 9 and TGFβ
while cytokines produced by the tumor cells (e.g., GM-CSF, IL-6,
and VEGF) limit differentiation of myeloid cells and promote
MDSC development (41). Production of TGFβ, VEGF, PGE2,
and IL-10 by tumor endothelial cells can also act directly on
T cells to suppress their function (42). MDSC have also been
shown to accumulate in the spleen, blood, and tumor DLN (41).
A study from Watanabe et al., demonstrated that reconstitution
of lethally irradiated mice with spleen cells from tumor-bearing
mice was sufficient to induce T cell suppression within DLNs
upon inoculation with tumor cells (41), showing the suppressive
capacity of splenic derived MDSCs. Our data clearly shows that
by day 22 post-tumor injection, intratumoral donor OT-I T cells
express high levels of inhibitory receptors, decreased cytokine
production, and reduced proliferative capacity—all of which are
indicators of T cell exhaustion. Conversely, donor OT-I T cells
within the spleens of AE17sOVAmesothelioma-bearing mice did
not display an exhausted phenotype, while T cells in the tumor
DLN showed a partially exhausted phenotype when mice were
challenged with AE17sOVA mesothelioma tumor cells. While
the Watanabe study assessed T cell suppression mediated by
splenic MDSCs in new host mice using tumor DLN as a readout,
our study addressed overall T cell functionality ex vivo from the
specific tissue microenvironments.
Tregs play a major role in modulating effector T cell responses,
and their role in inhibiting effective anti-tumor CTL responses
within tumors have been well-described. Largely, a high ratio
of Treg to effector T cells within a tumor indicates a worse
patient prognosis (43), and in some studies the frequency
of Treg within the total CD4
+ tumor-infiltrating lymphocyte
population was found to be >60% (44). While there is evidence
of direct Tregs suppression of effector T cells via cell-to-cell
contact (45), the impact of Tregs on the tumor microenvironment
and immune cells from the secretion of TGFβ and IL-10 is a
major contributor to the immunosuppressive environment of
tumors (46). Treg-mediated suppression of tumor-specific CTL
responses have also been identified within the tumor DLN, such
as the identification of TGFβ-secreting Tregs in tumor DLN
promoting tumor malignancy in breast cancer (47). There is
also evidence of early skewing of differentiating CD4+ T cells
toward induced Tregs rather than effector CD4
+ T cells in the
TDLN (48). Further, local effector CTL failure in mesothelioma
is not mediated by CD4+CD25+FoxP3+ Treg cells, as while Tregs
influence CTL responses when tumors are small, other immune
suppressor cells (macrophages, in particular) play a major role
in inhibiting effector CTL (49). It is therefore clear that these
different, spatially-separated microenvironments play a crucial
role in regulating and modulating the development of effector T
cell responses in cancer; gaining a better understanding of the
interplay between the microenvironment and development of
CTL exhaustion may also aid the development or application of
novel checkpoint blockade therapies.
Another important consideration in the development of T
cell exhaustion is antigen abundance. It has previously been
demonstrated that during chronic LCMV viral infection, the
amount of antigen recognized by T cells early on during infection
directly influences their subsequent development into effector
or exhausted T cells (2, 50). Using a modified strain of LCMV
clone 13 wherein only the gp33 expression level was altered,
Utzschneider et al. demonstrated that at 4 weeks post-infection,
decreasing the amount of gp33 expression while maintaining
all other chronic infection factors limited the development of T
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cell exhaustion in TCR transgenic P14 T cells (which specifically
recognize the gp33 epitope of LCMV). Similar results were
observed within the endogenous virus specific CD8+ T cells.
As many similarities have been observed between exhausted T
cells from chronic LCMV infection and cancer models, it is
therefore possible that the differences in phenotype observed
between the tumor, tumor DLN and spleen are influenced by
differing levels of antigen in the environment during early T cell
activation. CTL from spleens during LCMV infection are fully
exhausted while high viral loads of LCMV can be found in the
spleen and many other tissues. It is likely that tumor antigen in
AE17sOVA bearing mice, may be found in the spleen as well but
at a lower level than the tumor DLN and the tumor itself, and
this could then influence the lower level of exhaustion found in
the spleen and the intermediate exhaustion phenotype observed
in tumor-specific CTL isolated from the tumor DLN. Like B16-
OVA, we also believe that AE17sOVA tumors experience the
loss of OVA-antigen over time, as we have found lower OVA
expression levels in large tumors (unpublished data) and this loss
could be reflective of immune evasion in response to SIINFEKL-
specific CTLs.
It is apparent that although significant progress has beenmade
in regards to the development of cancer immunotherapies, there
remains a need to identify new and enhance existing therapies.
There is also a need to define biomarkers that can predict the
likelihood that a patient will respond to these therapies, as the
current regiment of anti-PD-1 and anti-CTLA-4 treatment can
have severe side effects and <50% of patients demonstrate at
least a partial response. It is therefore of great use to identify
model systems of T cell exhaustion, such as AE17sOVA, for use
in studies assessing the effectiveness of combination checkpoint
blockade therapy. It is not uncommon for animal studies using
tumors that express strong antigens such as OVA to inject
mice at a young age, and therefore immunologically immature,
or require the use of immune incompetent hosts in order to
avoid spontaneous tumor rejection (51). Having a model where
immunologically mature mice can be injected with a tumor that
carries a model antigen allows for studies of tumor exhaustion
that are more relevant to cancer patients. By demonstrating
that tissue niches influence the amount of CTL exhaustion,
our study also highlights the importance of the environment
from which cells are isolated for analysis. For translational
applications, analyzing tumor-specific T cell responses from the
blood or spleen of tumor-bearing mice may be more relevant
when comparing to human PBMCs than T cells isolated from
the tumor itself. In conclusion, our study validates the use of
the AE17sOVA tumor model system as a mechanism to study
CTL exhaustion during cancer in an antigen-specific manner and
has yielded new insights into the contribution of different tissue
microenvironments in the development of T cell exhaustion
in vivo.
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